Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

[FMR1 PREMUTATION CARRIERS - ARE THEY REALLY ASYMPTOMATIC?]

Elizur S, Berkenstadt M, Ries-Levavi L, Gruber N, Pinhas-Hamiel O, Hassin-Baer S, Raas-Rothschild A, Raanani H, Cukierman-Yaffe T, Orvieto R, Cohen Y, Gabis L.

Harefuah. 2018 Apr;157(4):241-244. Review. Hebrew.

PMID:
29688643
2.

Expanding the global prevalence of spinocerebellar ataxia type 42.

Ngo K, Aker M, Petty LE, Chen J, Cavalcanti F, Nelson AB, Hassin-Baer S, Geschwind MD, Perlman S, Italiano D, Laganà A, Cavallaro S, Coppola G, Below JE, Fogel BL.

Neurol Genet. 2018 Apr 5;4(3):e232. doi: 10.1212/NXG.0000000000000232. eCollection 2018 Jun. No abstract available.

3.

Evolution of echovirus 11 in a chronically infected immunodeficient patient.

Laassri M, Zagorodnyaya T, Hassin-Baer S, Handsher R, Sofer D, Weil M, Karagiannis K, Simonyan V, Chumakov K, Shulman L.

PLoS Pathog. 2018 Mar 19;14(3):e1006943. doi: 10.1371/journal.ppat.1006943. eCollection 2018 Mar.

4.

Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease.

Blauwendraat C, Kia DA, Pihlstrøm L, Gan-Or Z, Lesage S, Gibbs JR, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Chung SJ, Goldwurm S, Toft M, Schulte C; International Parkinson's Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Hernandez D, Singleton AB, Nalls MA, Brice A, Scholz SW, Wood NW.

Neurobiol Aging. 2018 Apr;64:159.e5-159.e8. doi: 10.1016/j.neurobiolaging.2017.12.012. Epub 2017 Dec 20.

PMID:
29398121
5.

Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study.

Cohen OS, Rigbi A, Yahalom G, Warman-Alaluf N, Nitsan Z, Zangen A, Hassin-Baer S.

J Clin Neurophysiol. 2018 Mar;35(2):159-165. doi: 10.1097/WNP.0000000000000455.

PMID:
29373395
6.

Localized myofascial pain responds better than referring myofascial pain to botulinum toxin injections.

Abboud WA, Hassin-Baer S, Joachim M, Givol N, Yahalom R.

Int J Oral Maxillofac Surg. 2017 Nov;46(11):1417-1423. doi: 10.1016/j.ijom.2017.04.020. Epub 2017 May 15.

PMID:
28521968
7.

The impact of early versus late levodopa administration.

Yahalom G, Cohen OS, Warmann-Alaluf N, Shabat C, Strauss H, Elincx-Benizri S, Israeli-Korn S, Stein E, Greenbaum L, Hassin-Baer S.

J Neural Transm (Vienna). 2017 Apr;124(4):471-476. doi: 10.1007/s00702-016-1669-4. Epub 2016 Dec 21.

PMID:
28004202
8.

Sexual Preoccupation Behavior in Parkinson's Disease.

Bronner G, Hassin-Baer S, Gurevich T.

J Parkinsons Dis. 2017;7(1):175-182. doi: 10.3233/JPD-160926. Review.

PMID:
27802244
9.

Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.

Elincx-Benizri S, Glik A, Merkel D, Arad M, Freimark D, Kozlova E, Cabantchik I, Hassin-Baer S.

J Child Neurol. 2016 Jul;31(8):1036-40. doi: 10.1177/0883073816636087. Epub 2016 Mar 29.

PMID:
27029487
10.

Decreased Anti-Parkinson's Therapy during Hospitalization due to Infectious Diseases is Associated with Worse Prognosis.

Segal O, Hassin-Baer S, Kliers I, Gringouz I, Dagan A, Cohen S, Segal G.

CNS Neurosci Ther. 2016 May;22(5):423-5. doi: 10.1111/cns.12545. Epub 2016 Mar 25. No abstract available.

PMID:
27012371
11.

Repetitive deep transcranial magnetic stimulation for motor symptoms in Parkinson's disease: A feasibility study.

Cohen OS, Orlev Y, Yahalom G, Amiaz R, Nitsan Z, Ephraty L, Rigbi A, Shabat C, Zangen A, Hassin-Baer S.

Clin Neurol Neurosurg. 2016 Jan;140:73-8. doi: 10.1016/j.clineuro.2015.11.017. Epub 2015 Nov 24.

PMID:
26658034
12.

Can the disease course in Parkinson's disease be slowed?

Korczyn AD, Hassin-Baer S.

BMC Med. 2015 Dec 10;13:295. doi: 10.1186/s12916-015-0534-x.

13.

Low Norton Scale Score Predicts Worse Outcomes for Parkinson's Disease Patients Hospitalized Due to Infection.

Segal O, Hassin-Baer S, Kliers I, Cale' KS, Segal G.

Gerontol Geriatr Med. 2015 Sep 23;1:2333721415608139. doi: 10.1177/2333721415608139. eCollection 2015 Jan-Dec.

14.

Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias.

Bronner G, Aharon-Peretz J, Hassin-Baer S.

Handb Clin Neurol. 2015;130:297-323. doi: 10.1016/B978-0-444-63247-0.00017-1. Review.

PMID:
26003251
15.

Decreased dopaminergic treatment of hospitalized Parkinson's disease patients during infectious diseases is associated with poor outcomes.

Segal O, Hassin-Baer S, Rosman M, Segal G.

J Clin Neurosci. 2015 Aug;22(8):1272-4. doi: 10.1016/j.jocn.2015.02.010. Epub 2015 Apr 22.

PMID:
25911502
16.

The neuropsychological profile of patients with 3-methylglutaconic aciduria type III, Costeff syndrome.

Sofer S, Schweiger A, Blumkin L, Yahalom G, Anikster Y, Lev D, Ben-Zeev B, Lerman-Sagie T, Hassin-Baer S.

Am J Med Genet B Neuropsychiatr Genet. 2015 Apr;168B(3):197-203. doi: 10.1002/ajmg.b.32296. Epub 2015 Feb 5.

PMID:
25657044
17.

Exploring determinants of progression in Parkinson's disease. Is there a difference among Jewish ethnic groups?

Orlev Y, Yahalom G, Cohen OS, Elincx-Benizri S, Kozlova E, Inzelberg R, Goldbourt U, Hassin-Baer S.

Parkinsonism Relat Disord. 2015 Mar;21(3):184-8. doi: 10.1016/j.parkreldis.2014.10.009. Epub 2014 Oct 18.

PMID:
25550275
18.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

19.

Genetic movement disorders in patients of Jewish ancestry.

Inzelberg R, Hassin-Baer S, Jankovic J.

JAMA Neurol. 2014 Dec;71(12):1567-72. doi: 10.1001/jamaneurol.2014.1364. Review.

PMID:
25347348
20.

The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma.

Elincx-Benizri S, Inzelberg R, Greenbaum L, Cohen OS, Yahalom G, Laitman Y, Djaldetti R, Orlev Y, Scope A, Azizi E, Friedman E, Hassin-Baer S.

J Mol Neurosci. 2014 Dec;54(4):820-5. doi: 10.1007/s12031-014-0425-1. Epub 2014 Oct 5.

PMID:
25284244
21.

Costeff syndrome: clinical features and natural history.

Yahalom G, Anikster Y, Huna-Baron R, Hoffmann C, Blumkin L, Lev D, Tsabari R, Nitsan Z, Lerman SF, Ben-Zeev B, Pode-Shakked B, Sofer S, Schweiger A, Lerman-Sagie T, Hassin-Baer S.

J Neurol. 2014 Dec;261(12):2275-82. doi: 10.1007/s00415-014-7481-x. Epub 2014 Sep 9.

PMID:
25201222
22.

Correlates of quality of sexual life in male and female patients with Parkinson disease and their partners.

Bronner G, Cohen OS, Yahalom G, Kozlova E, Orlev Y, Molshatzki N, Strauss H, Hassin-Baer S.

Parkinsonism Relat Disord. 2014 Oct;20(10):1085-8. doi: 10.1016/j.parkreldis.2014.07.003. Epub 2014 Jul 12.

PMID:
25131540
23.

Cardiac stress test is normal in pre-motor Parkinson's disease.

Yahalom G, Maor E, Hassin-Baer S, Segev S, Sidi Y, Kivity S.

Mov Disord. 2014 Aug;29(9):1158-62. doi: 10.1002/mds.25943. Epub 2014 Jun 20.

PMID:
24954917
24.

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.

Yahalom G, Orlev Y, Cohen OS, Kozlova E, Friedman E, Inzelberg R, Hassin-Baer S.

Mov Disord. 2014 Jul;29(8):1057-60. doi: 10.1002/mds.25931. Epub 2014 Jun 5.

PMID:
24903616
25.

Enhanced creative thinking under dopaminergic therapy in Parkinson disease.

Faust-Socher A, Kenett YN, Cohen OS, Hassin-Baer S, Inzelberg R.

Ann Neurol. 2014 Jun;75(6):935-42. doi: 10.1002/ana.24181. Epub 2014 Jun 10.

PMID:
24816898
26.

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Kaplan N, Vituri A, Korczyn AD, Cohen OS, Inzelberg R, Yahalom G, Kozlova E, Milgrom R, Laitman Y, Friedman E, Rosset S, Hassin-Baer S.

J Mol Neurosci. 2014 Jun;53(2):183-8. doi: 10.1007/s12031-014-0276-9. Epub 2014 Mar 15.

PMID:
24633632
27.

A deficit in optimizing task solution but robust and well-retained speed and accuracy gains in complex skill acquisition in Parkinson׳s disease: multi-session training on the Tower of Hanoi Puzzle.

Vakil E, Hassin-Baer S, Karni A.

Neuropsychologia. 2014 May;57:12-9. doi: 10.1016/j.neuropsychologia.2014.02.005. Epub 2014 Feb 11.

PMID:
24530238
28.

Asymmetric dopamine loss differentially affects effort to maximize gain or minimize loss.

Porat O, Hassin-Baer S, Cohen OS, Markus A, Tomer R.

Cortex. 2014 Feb;51:82-91. doi: 10.1016/j.cortex.2013.10.004. Epub 2013 Oct 30.

PMID:
24267688
29.

The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.

Greenbaum L, Israeli-Korn SD, Cohen OS, Elincx-Benizri S, Yahalom G, Kozlova E, Strauss H, Molshatzki N, Inzelberg R, Spiegelmann R, Israel Z, Hassin-Baer S.

Parkinsonism Relat Disord. 2013 Nov;19(11):1053-6. doi: 10.1016/j.parkreldis.2013.07.005. Epub 2013 Aug 6.

PMID:
23932063
30.

Subthalamic nucleus deep brain stimulation does not improve visuo-motor impairment in Parkinson's disease.

Israeli-Korn SD, Hocherman S, Hassin-Baer S, Cohen OS, Inzelberg R.

PLoS One. 2013 Jun 11;8(6):e65270. doi: 10.1371/journal.pone.0065270. Print 2013.

31.

Parkinson's disease genes do not segregate with breast cancer genes' loci.

Kravitz E, Laitman Y, Hassin-Baer S, Inzelberg R, Friedman E.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1464-72. doi: 10.1158/1055-9965.EPI-13-0472. Epub 2013 Jun 13.

32.

Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.

Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S.

Clin Neuropharmacol. 2013 May-Jun;36(3):78-83. doi: 10.1097/WNF.0b013e318288076a.

PMID:
23673909
33.

Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.

Greenbaum L, Goldwurm S, Zozulinsky P, Lifschytz T, Cohen OS, Yahalom G, Cilia R, Tesei S, Asselta R, Inzelberg R, Kohn Y, Hassin-Baer S, Lerer B.

J Mol Neurosci. 2013 Oct;51(2):380-8. doi: 10.1007/s12031-013-0020-x. Epub 2013 May 12.

PMID:
23666822
34.

Analysis of LMNB1 duplications in autosomal dominant leukodystrophy provides insights into duplication mechanisms and allele-specific expression.

Giorgio E, Rolyan H, Kropp L, Chakka AB, Yatsenko S, Di Gregorio E, Lacerenza D, Vaula G, Talarico F, Mandich P, Toro C, Pierre EE, Labauge P, Capellari S, Cortelli P, Vairo FP, Miguel D, Stubbolo D, Marques LC, Gahl W, Boespflug-Tanguy O, Melberg A, Hassin-Baer S, Cohen OS, Pjontek R, Grau A, Klopstock T, Fogel B, Meijer I, Rouleau G, Bouchard JP, Ganapathiraju M, Vanderver A, Dahl N, Hobson G, Brusco A, Brussino A, Padiath QS.

Hum Mutat. 2013 Aug;34(8):1160-71. doi: 10.1002/humu.22348. Epub 2013 May 28. Erratum in: Hum Mutat. 2014 Jan;35(1):149.

35.

Effects of asymmetric dopamine depletion on sensitivity to rewarding and aversive stimuli in Parkinson's disease.

Maril S, Hassin-Baer S, Cohen OS, Tomer R.

Neuropsychologia. 2013 Apr;51(5):818-24. doi: 10.1016/j.neuropsychologia.2013.02.003. Epub 2013 Feb 17.

PMID:
23422331
36.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
37.

The frontal assessment battery as a tool for evaluation of frontal lobe dysfunction in patients with Parkinson disease.

Cohen OS, Vakil E, Tanne D, Molshatzki N, Nitsan Z, Hassin-Baer S.

J Geriatr Psychiatry Neurol. 2012 Jun;25(2):71-7. doi: 10.1177/0891988712445087.

PMID:
22689698
38.

Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate.

Nissenkorn A, Hassin-Baer S, Lerman SF, Levi YB, Tzadok M, Ben-Zeev B.

J Child Neurol. 2013 Feb;28(2):155-60. doi: 10.1177/0883073812441999. Epub 2012 May 1.

PMID:
22550086
39.

The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.

Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R, Djaldetti R, Nitsan Z, Ephraty L, Tunkel O, Kozlova E, Inzelberg L, Kaplan N, Fixler Mehr T, Mory A, Dagan E, Schechtman E, Friedman E, Hassin-Baer S.

Neurology. 2012 Mar 13;78(11):781-6. doi: 10.1212/WNL.0b013e318249f673. Epub 2012 Feb 8.

PMID:
22323743
40.

Exploring hypersexual behavior in men with Parkinson's disease: is it compulsive sexual behavior?

Bronner G, Hassin-Baer S.

J Parkinsons Dis. 2012;2(3):225-34. doi: 10.3233/JPD-2012-012098.

PMID:
23938230
41.

Gender effect on time to levodopa-induced dyskinesias.

Hassin-Baer S, Molchadski I, Cohen OS, Nitzan Z, Efrati L, Tunkel O, Kozlova E, Korczyn AD.

J Neurol. 2011 Nov;258(11):2048-53. doi: 10.1007/s00415-011-6067-0. Epub 2011 May 1.

PMID:
21533825
42.

Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up.

Hassin-Baer S, Hattori N, Cohen OS, Massarwa M, Israeli-Korn SD, Inzelberg R.

Mov Disord. 2011 Mar;26(4):719-22. doi: 10.1002/mds.23456. Epub 2011 Jan 21.

PMID:
21506149
43.

High prevalence of malignant melanoma in Israeli patients with Parkinson's disease.

Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Aharon-Peretz J, Milo R, Schwartz M, Huberman M, Gilead L, Barchana M, Liphshiz I, Fitzer-Attas C, Giladi N.

J Neural Transm (Vienna). 2011 Aug;118(8):1199-207. doi: 10.1007/s00702-011-0580-2. Epub 2011 Feb 5.

PMID:
21298300
44.

Immunology, autoimmunity, and autoantibodies in Parkinson's disease.

Benkler M, Agmon-Levin N, Hassin-Baer S, Cohen OS, Ortega-Hernandez OD, Levy A, Moscavitch SD, Szyper-Kravitz M, Damianovich M, Blank M, Chapman J, Shoenfeld Y.

Clin Rev Allergy Immunol. 2012 Apr;42(2):164-71. doi: 10.1007/s12016-010-8242-y.

PMID:
21234712
45.

Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy (ADLD) with autonomic symptoms.

Schuster J, Sundblom J, Thuresson AC, Hassin-Baer S, Klopstock T, Dichgans M, Cohen OS, Raininko R, Melberg A, Dahl N.

Neurogenetics. 2011 Feb;12(1):65-72. doi: 10.1007/s10048-010-0269-y. Epub 2011 Jan 12.

PMID:
21225301
46.

Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?

Hassin-Baer S, Cohen OS, Vakil E, Molshazki N, Sela BA, Nitsan Z, Chapman J, Tanne D.

J Neural Transm (Vienna). 2011 Apr;118(4):539-43. doi: 10.1007/s00702-010-0535-z. Epub 2010 Dec 16.

PMID:
21161711
47.

The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.

Molchadski I, Korczyn AD, Cohen OS, Katzav A, Nitzan Z, Chapman J, Hassin-Baer S.

Acta Neurol Scand. 2011 Feb;123(2):117-21. doi: 10.1111/j.1600-0404.2010.01352.x.

PMID:
21108621
48.

Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson's disease.

Porat O, Cohen OS, Schwartz R, Hassin-Baer S.

J Neuropsychiatry Clin Neurosci. 2009 Fall;21(4):398-405. doi: 10.1176/jnp.2009.21.4.398.

PMID:
19996248
49.

The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.

Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E.

J Neurol. 2009 Mar;256(3):483-7. doi: 10.1007/s00415-009-0117-x. Epub 2009 Mar 24.

PMID:
19412725
50.

Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.

Djaldetti R, Hassin-Baer S, Farrer MJ, Vilariño-Güell C, Ross OA, Kolianov V, Yust-Katz S, Treves TA, Barhum Y, Hulihan M, Melamed E.

J Neural Transm (Vienna). 2008 Sep;115(9):1279-84. doi: 10.1007/s00702-008-0074-z. Epub 2008 Jul 30.

PMID:
18665323

Supplemental Content

Loading ...
Support Center